COVID Vaccine Distribution: A four-phase plan

Pfizer, in cooperation with German-based BioNTech, crossed an historic milestone this week when they submitted to the Food and Drug Administration an emergency use authorization (EUA) for a COVID-19 vaccine. The data will quickly be analyzed by FDA and then submitted to an independent advisory panel in early December for approval, which then also will receive a necessary ‘green light’ from the Centers for Disease Control, particularly regarding the rollout process for Pfizer/BioNTech’s vaccine on a prioritization scale. Read more…